UPDATE: Morgan Stanley Upgrades Forest Laboratories Ahead of Further Financial Upside

In a report published Tuesday, Morgan Stanley analyst David Risinger upgraded the rating on Forest Laboratories FRX from Equal-Weight to Overweight, and named an $86.00 price target. In the report, Morgan Stanley noted, “Our Base Case is an earnings and multiple call: cons under-estimates durability of growth. We raised F15E (Mar) EPS 25% from $3.13 to $3.90 (5% above cons) and F16E EPS 23% from $3.86 to $4.73 (9% above cons). Cons is not fully updated for the Aptalis close Feb 3rd, but we believe investors under-appreciate Namenda earnings durability in the wake of the hard conversion to longer patent life XR announced late-Friday Feb 14th. We est. Forest F16-F21 5-yr EPS CAGR of 8%, and we believe cons under-estimates durability of growth and P/E will rise.” Forest Laboratories closed on Friday at $71.39.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesAnalyst RatingsDavid RisingerMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!